Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) will release its earnings data after the market closes on Thursday, November 7th. Persons that are interested in participating in the company’s earnings conference call can do so using this link.
Cumberland Pharmaceuticals Stock Performance
Shares of CPIX traded up $0.01 during mid-day trading on Tuesday, reaching $1.15. 42,090 shares of the company’s stock traded hands, compared to its average volume of 12,976. Cumberland Pharmaceuticals has a 12 month low of $1.07 and a 12 month high of $2.36. The stock has a market capitalization of $16.22 million, a P/E ratio of -1.58 and a beta of 0.22. The business’s 50-day moving average price is $1.26 and its 200-day moving average price is $1.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.26 and a current ratio of 1.44.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals in a report on Saturday. They set a “hold” rating on the stock.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Further Reading
- Five stocks we like better than Cumberland Pharmaceuticals
- Which Wall Street Analysts are the Most Accurate?
- Palantir Cracks $50, Is There Still Time to Get on Board?
- What is a Special Dividend?
- Insider Buying Signals Upside for These 3 Stocks
- What is a Death Cross in Stocks?
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
